RfP opens: 6 October 2022
Deadline: 14 December 2022, 2 pm (Central European Time) (extended from 22 November)
PURPOSE AND RESEARCH FIELDS
This RFP will support research designed to develop novel small-molecule antivirals targeting pandemic influenza. PAD funding can support preclinical activities and phase I clinical trials, but not later stage clinical trials. Special consideration will be given to therapeutic modalities that are suitable for deployment in low resource settings. Researchers from around the world are encouraged to submit proposals.
Proposals should be consistent with at least one of these 4 areas:
- Direct acting antivirals with data demonstrating clear differentiation from currently marketed influenza antiviral products
- Host targeted therapies with data demonstrating clear benefit over currently marketed influenza virus therapeutics
- Compounds that target multiple pathways or mechanisms to reduce the likelihood of resistance emergence
- Compounds demonstrating activity against drug resistant influenza variants
In addition to improved clinical efficacy over standard of care, attributes that define differentiation include shorter duration of therapy, reduced dosing frequency, improved safety, lower cost of goods, higher barrier to resistance and/or novel targets/mechanism of action.
Projects can be anchored at any type of research organization, including academia, not-for profit and commercial organizations.
HOW TO APPLY
The full call text, including eligibility criteria, funding framework, details of the application process, and instructions on how to apply and what information to include in an application can be found in the guidelines – link via button below.
The application must be completed in English, contain all the information requested in the guidelines, and submitted using the Novo Nordisk Foundation’s application and grant management system, NORMA – link to application system via button below.
The PAD founding partners Bill & Melinda Gates Foundation, Open Philanthropy and Novo Nordisk Foundation will have access to all the proposals submitted to this RfP.
Deadline for submission of concept note: 14 December 2022 at 2 pm Central European Time
Please be aware that projects that fall outside the 4 defined areas and projects on vaccines, antibody and nanobody therapy, diagnostics, clinical trials (Phase II, III, IV), formulation development and epidemiology are excluded from the RFP and will not be considered for funding.